Trial Profile
Prediction of adverse events in patients with EGFR-mutant non-small cell lung cancer using population pharmacokinetics of afatinib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Apr 2020
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Apr 2020 Status changed from active, no longer recruiting to completed.
- 04 Apr 2017 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 27 Jul 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan